Scientific Management and Operations, Science Policy, Alzheimer's Disease, and Alzheimer’s Disease Related Dementias
Dr. Jordan Gladman leads strategic efforts that optimize organizational, budgetary, policy, and communication efforts in support of our scientific priorities. He leads projects focused on enhancing operations across the OD, and between the OD and the intramural and extramural Divisions, with the goal of strengthening the partnerships between science and administration and accelerating our research.
Most recently, Jordan worked in the NIH Office of the Director as the Special Assistant to the NIH Principal Deputy Director, Larry Tabak. While in the NIH OD, he served as the executive secretary for the ACD Working Group on Enhancing Rigor, Transparency, and Translatability in Animal Research, which will be making a final report to the ACD on June 11. Additionally, he helped to coordinate the 2020 presidential transition materials process, the reviews of the IC diversity and health disparities plans, and he helped with the early development of the UNITE initiative. Prior to that he worked in the NINDS Neurodegeneration Cluster as a Health Program Specialist. There he focused on the NINDS response to the National Plan to Address Alzheimer’s Disease and provided key coordination and support for the NINDS/NIH Alzheimer's Disease-Related Dementias (ADRD) extramural research program.
Jordan received his B.S. in Molecular Biology from Ohio Northern University. During this time he worked as an undergraduate research intern in the microbiology laboratories of the Aerosol Science division of Battelle Memorial Institute. He obtained his Ph.D. from the Integrated Biomedical Science Graduate Program at The Ohio State University. Under the direction of Dr. Dawn S. Chandler he characterized the mouse Smn gene and developing a knock-in Smn C>T mouse modal of spinal muscular atrophy (SMA). Upon graduation, he joined the laboratory of Dr. Mani Mahadevan at the University of Virginia as a postdoctoral research associate, where he studied the molecular mechanism underlying myotonic dystrophy type 1 (DM1).